Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) Short Interest Down 28.2% in February

Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) was the target of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 543,400 shares, a decline of 28.2% from the February 13th total of 756,800 shares. Approximately 8.7% of the company’s shares are short sold. Based on an average daily trading volume, of 860,500 shares, the short-interest ratio is presently 0.6 days.

Bullfrog AI Price Performance

Shares of NASDAQ:BFRG opened at $1.72 on Monday. Bullfrog AI has a 1 year low of $1.43 and a 1 year high of $4.84. The business has a 50 day simple moving average of $2.45 and a two-hundred day simple moving average of $2.41. The firm has a market capitalization of $14.99 million, a PE ratio of -2.02 and a beta of 0.32.

Bullfrog AI (NASDAQ:BFRG) last announced its earnings results on Friday, March 14th. The company reported ($0.18) earnings per share (EPS) for the quarter.

Institutional Trading of Bullfrog AI

Large investors have recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in shares of Bullfrog AI in the fourth quarter valued at approximately $30,000. Geode Capital Management LLC boosted its holdings in shares of Bullfrog AI by 31.0% in the fourth quarter. Geode Capital Management LLC now owns 47,093 shares of the company’s stock valued at $94,000 after purchasing an additional 11,140 shares during the period. Finally, Two Sigma Securities LLC purchased a new stake in shares of Bullfrog AI in the fourth quarter valued at approximately $41,000. Hedge funds and other institutional investors own 0.96% of the company’s stock.

About Bullfrog AI

Bullfrog AI Holdings, Inc, through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data.